Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Stryker Neurovascular

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Stryker Neurovascular

Regulatory records
8
Linked recall entries
1
Headquarters
Not reported
Brand website
stryker.com
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 8 FDA records to the applicant name Stryker Neurovascular. The collection includes 3 510(k) clearances. It includes 1 original PMA approval. 2 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from May 16, 2019 to Oct 24, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code OUT appears in 3 of the 8 linked filings. The collection spans 3 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P170024, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 47900 Bayside Pkwy., Fremont, CA, 94538. Recorded on P180031/S012, decision dated Oct 24, 2026.

Changes described in PMA records

P180031/S012: Neuroform Atlas Stent System

FDA approved supplement S012 to PMA P180031 for the Neuroform Atlas Stent System on October 24, 2026. The supplement covers a manufacturing site at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica, for postlaser cutting operations of the Neuroform Atlas stent component.

This is a location change for a manufacturer, not a new approval of the whole system. The stated scope is limited to postlaser cutting operations at the named Costa Rica site. The source statement does not describe any change to indications, labeling, design, or clinical data, and it does not provide evidence of safety or effectiveness beyond the administrative approval record.

FDA approval-order wording

approval for a manufacturing site located at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica for the postlaser cutting operations of the Neuroform Atlas stent component

Oct 24, 2026 · Normal 180 Day Track No User Fee

P170024/S026: Surpass Evolve; Surpass Elite FDS

FDA’s recorded scope: approval for addition of a new supplier for the polytetrafluoroethylene (PTFE) material used in the Introducer Sheath Assembly for the Surpass Flow Diverter System (Evolve and Elite)

Jun 26, 2026 · 30-Day Notice

P170024/S024: Surpass Streamline Flow Diverter

FDA’s recorded scope: approval for manufacturing process improvements for the manufacturing line for the Surpass Evolve Flow Diverter System (FDS) and Surpass Elite Flow Diverter System, as well as Stent Loader equipment upgrades for Surpass Evolve FDS.

Aug 20, 2025 · 30-Day Notice

P180031: Neuroform Atlas Stent System

The FDA approved the Neuroform Atlas Stent System for use with neurovascular embolization coils in the anterior circulation of the neurovasculature. The approval covers endovascular treatment of patients 18 years or older with saccular wide-necked intracranial aneurysms, defined as neck width of 4 mm or greater or a dome-to-neck ratio below 2.

The device is limited to aneurysms arising from a parent vessel with a diameter of at least 2.0 mm and no more than 4.5 mm. The decision date is May 16, 2019, and the applicant is Stryker Neurovascular. The source statement describes the approved scope but does not provide independent proof of safety or clinical effectiveness.

FDA approval-order wording

Approved for use with neurovascular embolization coils in the anterior circulation of the neurovasculature for the endovascular treatment of patients greater or equal to 18 years of age with saccular wide-necked (neck width greater or equal to 4 mm or a dome-to-neck ratio of < 2) intracranial aneurysms arising from a parent vessel with a diameter of greater or equal to 2.0 mm and less than or equal to 4.5 mm.

May 16, 2019

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Stryker NeurovascularClass IIJul 1, 2026FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker NeurovascularPMA supplementOct 24, 2026FDA
Stryker Neurovascular510(k) clearanceOct 9, 2026FDA
Stryker NeurovascularPMA supplementAug 28, 2026FDA
Stryker Neurovascular510(k) clearanceJul 1, 2026FDA
Stryker NeurovascularPMA supplementJun 26, 2026FDA
Stryker Neurovascular510(k) clearanceFeb 11, 2026FDA
Stryker NeurovascularPMA supplementAug 20, 2025FDA
Stryker NeurovascularPMA approvalMay 16, 2019FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.